WASHINGTON – In a move that alarms public health advocates, the Trump administration has delayed the publication of a Centers for Disease Control and Prevention (CDC) report showcasing the significant benefits of the COVID-19 vaccine. This action intensifies concerns that the administration is actively working to undermine public trust in vaccines, potentially jeopardizing the health of vulnerable populations.

The delayed report, compiled by CDC scientists, reportedly demonstrates that the COVID-19 vaccine reduces the risk of emergency room visits and hospitalizations for healthy adults by approximately half during the winter of 2025. Acting CDC Director Jay Bhattacharya, a Trump appointee, has reportedly cited concerns about the research methodology as the reason for the delay. This justification is viewed with deep skepticism by many in the scientific community.

The delay comes amidst a broader pattern of attacks on science and public health by the Trump administration, which has a troubling record of downplaying the severity of public health crises and promoting misinformation. Health Secretary Robert F. Kennedy Jr., known for his anti-vaccine stance, and his appointees have consistently sought to obstruct vaccine research and weaken public health recommendations.

Dr. Fiona Havers, former senior advisor on vaccine policy at the CDC, sees this delay as a dangerous escalation. “This is definitely an escalation of this administration’s undermining of CDC science,” she stated, emphasizing the potential consequences for public health. Havers resigned from the CDC last year in protest of the administration’s approach to vaccine policy.

The CDC study found that between September and December of 2025, vaccinated healthy adults experienced a 55% reduction in COVID-related hospitalizations. Emergency and urgent care visits were also reduced by 50% among those who received the vaccine, according to reporting by the Washington Post. These findings are crucial for informing public health strategies and encouraging vaccination, particularly among communities disproportionately affected by COVID-19.

The methodology used in the report, known as “test-negative design,” has been a standard practice at the CDC for two decades. This approach compares vaccination rates among patients who are already sick, a necessary adaptation given the ethical considerations of conducting placebo-controlled trials when the CDC recommends widespread vaccination, Havers explained. The fact that a similar methodology was recently used in a report on the flu vaccine raises further questions about the motives behind the delay.